

Levent Kabasakal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4335021/publications.pdf>

Version: 2024-02-01

69
papers

1,810
citations

331670

21
h-index

276875

41
g-index

69
all docs

69
docs citations

69
times ranked

2218
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷ Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1976-1983.	6.4	166
2	⁶⁸ Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1461-1462.	6.4	127
3	Normal distribution pattern and physiological variants of ⁶⁸ Ga-PSMA-11 PET/CT imaging. <i>Nuclear Medicine Communications</i> , 2016, 37, 1169-1179.	1.1	126
4	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. <i>Nuclear Medicine Communications</i> , 2015, 36, 582-587.	1.1	125
5	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
6	Comparison of ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1271-1277.	6.4	119
7	The accuracy of ⁶⁸ Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1806-1812.	6.4	89
8	Can SUVmax values of Ga- ⁶⁸ -PSMA PET/CT scan predict the clinically significant prostate cancer?. <i>Nuclear Medicine Communications</i> , 2019, 40, 86-91.	1.1	83
9	Guidelines for radioiodinated MIBG scintigraphy in children. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, B45-B50.	6.4	80
10	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [¹⁷⁷ Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	6.4	72
11	FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 556-564.	6.4	57
12	Lu- ¹⁷⁷ -PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 62-68.	0.7	53
13	¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2018, 39, 789-796.	1.1	53
14	Evaluation of radiation safety in ¹⁷⁷ Lu-PSMA therapy and development of outpatient treatment protocol. <i>Journal of Radiological Protection</i> , 2016, 36, 269-278.	1.1	39
15	Guidelines for direct radionuclide cystography in children. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, B39-B44.	6.4	34
16	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. <i>Nuclear Medicine Communications</i> , 2017, 38, 149-155.	1.1	32
17	Correlation of technetium-99m MIBI and thallium-201 retention in solitary cold thyroid nodules with postoperative histopathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 713-720.	6.4	31
18	Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1500-1504.	6.4	30

#	ARTICLE	IF	CITATIONS
19	Technetium-99m ethylene dicysteine: a new renal tubular function agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 351-357.	6.4	29
20	Ictal and interictal SPECT findings in childhood absence epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2000, 9, 265-269.	2.0	29
21	Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 1084-1089.	1.1	22
22	Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a ¹⁷⁷ Lu-DOTA-minigastrin derivative. <i>Nuclear Medicine and Biology</i> , 2011, 38, 171-179.	0.6	21
23	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [¹⁷⁷ Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076.	6.4	20
24	Technetium-99m sestamibi uptake in human breast carcinoma cell lines displaying glutathione-associated drug-resistance. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 568-570.	2.1	18
25	Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. <i>Annals of Nuclear Medicine</i> , 2021, 35, 900-915.	2.2	18
26	Performance of F-18 Fluorocholine PET/CT for Detection of Hyperfunctioning Parathyroid Tissue in Patients with Elevated Parathyroid Hormone Levels and Negative or Discrepant Results in conventional Imaging. <i>Korean Journal of Radiology</i> , 2020, 21, 236.	3.4	17
27	Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria. <i>Nuclear Medicine Communications</i> , 2020, 41, 759-767.	1.1	16
28	Post-therapy imaging of ²²⁵ Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2711-2712.	6.4	15
29	A dynamic renal phantom for nuclear medicine studies. <i>Medical Physics</i> , 2005, 32, 530-538.	3.0	14
30	Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2013, 34, 727-732.	1.1	14
31	The Effect of P-Glycoprotein Function Inhibition With Cyclosporine A on the Biodistribution of Tc-99m Sestamibi. <i>Clinical Nuclear Medicine</i> , 2000, 25, 20.	1.3	12
32	Ectopic Parathyroid Adenoma Localized With MIBI Scintigraphy and Excised With Guide of Macroaggregated Human Serum Albumin Injection. <i>Clinical Nuclear Medicine</i> , 2010, 35, 151-153.	1.3	11
33	Comparison of ^{99m} Tc-HYNIC-TOC and HYNIC-TATE Octreotide Scintigraphy With FDG PET and ^{99m} Tc-MIBI in Local Recurrent or Distant Metastatic Thyroid Cancers. <i>Clinical Nuclear Medicine</i> , 2013, 38, 321-325.	1.3	11
34	Temporal relationship between gastroesophageal reflux and rate of gastric emptying in children. <i>Nuclear Medicine Communications</i> , 2010, 31, 1059-1062.	1.1	11
35	The Diagnostic Efficiency of ^{99m} Tc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with ¹¹¹ In-Pentetreotide in the Detection of Neuroendocrine Tumours. <i>Molecular Imaging and Radionuclide Therapy</i> , 2013, 22, 76-84.	0.7	11
36	The effects of exposure of ⁶⁰ Co on the oxidant/antioxidant status among radiation victims. <i>Journal of Environmental Radioactivity</i> , 2003, 64, 19-25.	1.7	8

#	ARTICLE	IF	CITATIONS
37	ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCANâ€¦. Radiation Protection Dosimetry, 2018, 182, 518-524.	0.8	8
38	Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy. Radiation and Environmental Biophysics, 2018, 57, 395-404.	1.4	7
39	Prognostic value of ADC measurements in predicting overall survival in patients undergoing 90Y radioembolization for colorectal cancer liver metastases. Clinical Imaging, 2019, 57, 124-130.	1.5	7
40	Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT. Clinical Nuclear Medicine, 2017, 42, e504-e505.	1.3	6
41	Is furosemide administration effective in improving the accuracy of determination of differential renal function by means of technetium-99m DMSA in patients with hydronephrosis. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1433-1437.	6.4	5
42	Is the I-131 whole-body scanning proper for follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?. Gynecologic Oncology, 2005, 99, 520.	1.4	5
43	Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers. Nuclear Medicine Communications, 2013, 34, 1190-1195.	1.1	5
44	Simplified determination of technetium-99m ethylenedicysteine clearance from a single plasma sample: What is the upper normal range?. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1556-1556.	2.1	4
45	Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1630-1636.	6.4	4
46	The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1660-1661.	6.4	4
47	[68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4523-4524.	6.4	4
48	Therapyâ€¦related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer Reports, 2020, 3, e1282.	1.4	3
49	Reproducibility of technetium-99m ethylenedicysteine clearance. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 900-902.	6.4	2
50	Intravascular radiation therapy with a Re-188 liquid-filled balloon in patients with in-stent restenosis. Nuclear Medicine Communications, 2010, 31, 746-752.	1.1	2
51	Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe. Clinical Nuclear Medicine, 2011, 36, 831-833.	1.3	2
52	Evaluation of Liver Stiffness After Radioembolization by Real-Time ShearWaveâ„¢ Elastography: Preliminary Study. CardioVascular and Interventional Radiology, 2015, 38, 957-963.	2.0	2
53	The Role of 68GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urology Journal, 2020, 18, 58-65.	0.4	2
54	Almost Complete Response with a Single Administration <sup>225</sup><sup>Ac</sup>-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary. Molecular Imaging and Radionuclide Therapy, 2022, 31, 139-141.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Gastrinoma and Insulinoma in a Patient With Multiple Endocrine Neoplasia. , 2005, 15, 151-153.		1
56	Procedure Guidelines for Lu-177 PSMA Radyoligand Treatment. , 2020, 6, 385-396.		1
57	Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT. , 2020, 6, 370-384.		1
58	Relationship between the OIH and 99Tcm-EC clearances. Nuclear Medicine Communications, 1994, 15, 1006-1007.	1.1	0
59	Sistatin C: bÅ¶brek iÅ¶levleri azalmakta olan Åocuklarda glomerÅ¼ler filtrasyon hÅ±zÅ± Å¶lÅ¶Å¼mÅ¼nde daha yararlıÅ± bir deÅ¶iÅ¶ken olabilir mi?. Turk Pediatri Arsivi, 2011, 46, 118-123.	0.9	0
60	MP20-15 THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	0
61	PET/CT in Treatment Response Evaluation of Colorectal Cancer. , 2021, 7, 241-245.		0
62	Ga-68 PSMA PET/CT in the Evaluation of Treatment Response in Prostate Cancer. , 2021, 7, 246-251.		0
63	Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy. Åeroonkoloji BÅ¼lteni, 2016, 15, 159-162.	0.1	0
64	Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor. Clinical Endoscopy, 2016, 49, 479-482.	1.5	0
65	Guideline for the Treatment of Liver Cancer with Y-90 Radiomicrosphere. , 2020, 6, 416-422.		0
66	Practical Guidance on Peptide Receptor Radionuclide Therapy. , 2020, 6, 406-415.		0
67	Guideline for PET/CT Imaging of Neuroendocrine Neoplasms with 68Ga-DOTA-conjugated Somatostatin Receptor Targeting Peptides. , 2020, 6, 397-405.		0
68	Nuclear Imaging and Treatment of Pheochromocytoma and Paragangliomas. , 2021, 7, 293-299.		0
69	PRRT in NETÅ¶s: Lu-177 PRRT and New Scope Alpha Treatment. , 2021, 7, 300-309.		0